See the DrugPatentWatch profile for Soliris
When does the Soliris (eculizumab) patent expire?
I don’t have enough specific, date-level patent information in the provided material to state an exact “Soliris patent expiry” date.
For up-to-date, drug-specific patent and exclusivity timelines (including which patents are listed and when they end), DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/ .
What “expiry” usually means for Soliris: patents vs. exclusivity
“Soliris patent expiry” can refer to different layers of market protection, including:
- patent expiration on specific compositions, methods, or formulations
- regulatory exclusivities that can extend market protection even after a patent ends
- litigation-driven delays where a generic or biosimilar challenge does not enter immediately
Those details vary by jurisdiction (U.S., EU, etc.) and by which specific patent family is being asked about.
Will biosimilars/alternatives enter right after patent expiry?
Even after one patent expires, other blocking patents or exclusivity periods can delay entry. Also, biosimilar development and approval timelines (for an antibody biologic like Soliris) can take years beyond patent expiry, and legal challenges can further extend timelines.
If you tell me your country, I can narrow it down
Patent and exclusivity timelines differ by market. If you share whether you mean the U.S., EU, UK, or another country, I can help pinpoint what “expiry” typically applies there (patent vs. exclusivity) and what competitive entry timing to expect.
Source
- [1] https://www.drugpatentwatch.com/